SG Americas Securities LLC boosted its holdings in Omeros Co. (NASDAQ:OMER) by 138.9% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 12,154 shares of the biopharmaceutical company’s stock after acquiring an additional 7,067 shares during the quarter. SG Americas Securities LLC’s holdings in Omeros were worth $263,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also bought and sold shares of the company. Ingalls & Snyder LLC boosted its stake in shares of Omeros by 0.3% during the 3rd quarter. Ingalls & Snyder LLC now owns 5,161,035 shares of the biopharmaceutical company’s stock worth $111,582,000 after acquiring an additional 17,746 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Omeros by 5.4% in the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after buying an additional 94,280 shares during the period. State Street Corp boosted its position in shares of Omeros by 7.3% in the second quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after buying an additional 66,827 shares during the period. Northern Trust Corp boosted its position in shares of Omeros by 6.4% in the second quarter. Northern Trust Corp now owns 572,576 shares of the biopharmaceutical company’s stock worth $11,397,000 after buying an additional 34,328 shares during the period. Finally, Tocqueville Asset Management L.P. boosted its position in shares of Omeros by 0.7% in the third quarter. Tocqueville Asset Management L.P. now owns 480,896 shares of the biopharmaceutical company’s stock worth $10,397,000 after buying an additional 3,430 shares during the period. Hedge funds and other institutional investors own 49.71% of the company’s stock.
A number of research firms recently issued reports on OMER. Maxim Group set a $24.00 price objective on Omeros and gave the company a “buy” rating in a research report on Tuesday, December 12th. HC Wainwright set a $30.00 target price on Omeros and gave the company a “buy” rating in a report on Wednesday, November 29th. Cowen lowered Omeros from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 2nd. Finally, Zacks Investment Research lowered Omeros from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. Five research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. Omeros has a consensus rating of “Buy” and a consensus price target of $34.14.
Shares of Omeros Co. (NASDAQ OMER) traded down $0.11 on Thursday, hitting $19.73. The stock had a trading volume of 755,604 shares, compared to its average volume of 643,264. The company has a quick ratio of 4.74, a current ratio of 4.77 and a debt-to-equity ratio of 8.99. Omeros Co. has a fifty-two week low of $8.71 and a fifty-two week high of $27.09. The firm has a market cap of $947.11, a P/E ratio of -15.29 and a beta of 3.56.
Omeros (NASDAQ:OMER) last posted its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.18. The company had revenue of $21.66 million during the quarter, compared to the consensus estimate of $17.82 million. The business’s revenue for the quarter was up 91.9% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) EPS. sell-side analysts anticipate that Omeros Co. will post -0.98 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Omeros Co. (NASDAQ:OMER) Shares Bought by SG Americas Securities LLC” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this story on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The correct version of this story can be read at https://www.dispatchtribunal.com/2018/01/11/sg-americas-securities-llc-has-263000-stake-in-omeros-co-omer.html.
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.